Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende Patientenratgeber
Erweiterte Suche
Anmelden
nach oben
Abdominal Radiology
Erschienen in:

06.04.2019 | Review

Hepatic disorders associated with exogenous sex steroids: MR imaging findings

verfasst von: Cathryn L. Hui, Zhen Jiang Lee

Erschienen in: Abdominal Radiology | Ausgabe 7/2019

Einloggen, um Zugang zu erhalten

Abstract

Objective

To describe the MRI findings of the effects of exogenous sex steroids on the liver.

Findings

Estrogens, progesterone and synthetic testosterone are exogenous sex steroids that may result in a variety of liver diseases, including tumour formation and vascular disorders. These hormones are mainly administered in the form of the oral contraceptive pill (OCP) and anabolic steroids. Both are implicated in hepatic adenoma formation. The HNF-1α-mutated and inflammatory adenoma subgroups are more commonly seen in association with the OCP whereas there is an increased incidence of the β-catenin positive subtype with anabolic steroid use. Furthermore, anabolic steroids are associated with hepatocellular carcinoma resulting from malignant transformation of β-catenin positive adenomas. The oral contraceptive pill may also induce vascular disorders within the liver, some of which are related to the prothrombotic effect of the hormones, such as hepatic and portal vein thrombosis. Other hepatic vascular abnormalities resulting from exogenous sex steroids include veno-occlusive disease and peliosis hepatis.
Literatur
1.
Katabathina VS, Menias CO, Shanbhogue AK, Jagirdar J, Paspulati RM, Prasad SR. Genetics and imaging of hepatocellular adenomas: 2011 update. Radiographics. 2011;31(6):1529–43.CrossRefPubMed
2.
Dhingra S, Fiel MI. Update on the new classification of hepatic adenomas: clinical, molecular, and pathologic characteristics. Arch Pathol Lab Med. 2014;138(8):1090–7.CrossRefPubMed
3.
McInnes MD, Hibbert RM, Inacio JR, Schieda N. Focal Nodular Hyperplasia and Hepatocellular Adenoma: Accuracy of Gadoxetic Acid-enhanced MR Imaging: A Systematic Review. Radiology. 2015;277(2):413–23.CrossRefPubMed
4.
Bioulac-Sage P, Laumonier H, Couchy G, Le Bail B, Sa Cunha A, Rullier A, et al. Hepatocellular adenoma management and phenotypic classification: the Bordeaux experience. Hepatology. 2009;50(2):481–9.CrossRefPubMed
5.
Yoneda N, Matsui O, Kitao A, Kozaka K, Kobayashi S, Sasaki M, et al. Benign Hepatocellular Nodules: Hepatobiliary Phase of Gadoxetic Acid-enhanced MR Imaging Based on Molecular Background. Radiographics. 2016;36(7):2010–27.CrossRefPubMed
6.
Rebouissou S, Imbeaud S, Balabaud C, Boulanger V, Bertrand-Michel J, Terce F, et al. HNF1alpha inactivation promotes lipogenesis in human hepatocellular adenoma independently of SREBP-1 and carbohydrate-response element-binding protein (ChREBP) activation. J Biol Chem. 2007;282(19):14437–46.CrossRefPubMed
7.
van Aalten SM, Thomeer MG, Terkivatan T, Dwarkasing RS, Verheij J, de Man RA, et al. Hepatocellular adenomas: correlation of MR imaging findings with pathologic subtype classification. Radiology. 2011;261(1):172–81.CrossRefPubMed
8.
Grazioli L, Bondioni MP, Haradome H, Motosugi U, Tinti R, Frittoli B, et al. Hepatocellular adenoma and focal nodular hyperplasia: value of gadoxetic acid-enhanced MR imaging in differential diagnosis. Radiology. 2012;262(2):520–9.CrossRefPubMed
9.
Ronot M, Bahrami S, Calderaro J, Valla DC, Bedossa P, Belghiti J, et al. Hepatocellular adenomas: accuracy of magnetic resonance imaging and liver biopsy in subtype classification. Hepatology. 2011;53(4):1182–91.CrossRefPubMed
10.
Bieze M, van den Esschert JW, Nio CY, Verheij J, Reitsma JB, Terpstra V, et al. Diagnostic accuracy of MRI in differentiating hepatocellular adenoma from focal nodular hyperplasia: prospective study of the additional value of gadoxetate disodium. AJR Am J Roentgenol. 2012;199(1):26–34.CrossRefPubMed
11.
Socas L, Zumbado M, Perez-Luzardo O, Ramos A, Perez C, Hernandez JR, et al. Hepatocellular adenomas associated with anabolic androgenic steroid abuse in bodybuilders: a report of two cases and a review of the literature. Br J Sports Med. 2005;39(5):e27.CrossRefPubMedPubMedCentral
12.
Hardt A, Stippel D, Odenthal M, Holscher AH, Dienes HP, Drebber U. Development of hepatocellular carcinoma associated with anabolic androgenic steroid abuse in a young bodybuilder: a case report. Case Rep Pathol. 2012;2012:195607.PubMedPubMedCentral
13.
Kitao A, Matsui O, Yoneda N, Kozaka K, Kobayashi S, Sanada J, et al. Hepatocellular Carcinoma with beta-Catenin Mutation: Imaging and Pathologic Characteristics. Radiology. 2015;275(3):708–17.CrossRefPubMed
14.
Solbach P, Potthoff A, Raatschen HJ, Soudah B, Lehmann U, Schneider A, et al. Testosterone-receptor positive hepatocellular carcinoma in a 29-year old bodybuilder with a history of anabolic androgenic steroid abuse: a case report. BMC Gastroenterol. 2015;15:60.CrossRefPubMedPubMedCentral
15.
Kitao A, Matsui O, Yoneda N, Kozaka K, Kobayashi S, Koda W, et al. Hypervascular hepatocellular carcinoma: correlation between biologic features and signal intensity on gadoxetic acid-enhanced MR images. Radiology. 2012;265(3):780–9.CrossRefPubMedPubMedCentral
16.
Sutherland T, Seale M, Yap K. Part 1: MRI features of focal nodular hyperplasia with an emphasis on hepatobiliary contrast agents. Journal of medical imaging and radiation oncology. 2014;58(1):50–5.CrossRefPubMed
17.
Mohajer K, Frydrychowicz A, Robbins JB, Loeffler AG, Reed TD, Reeder SB. Characterization of hepatic adenoma and focal nodular hyperplasia with gadoxetic acid. J Magn Reson Imaging. 2012;36(3):686–96.CrossRefPubMedPubMedCentral
18.
Sarma A, Shaaban AM, Heilbrun ME, Rezvani M. Two cases of near-complete regression of focal nodular hyperplasia of the liver: case reports and review of the literature. Radiology case reports. 2012;7(3).
19.
Mathieu D, Kobeiter H, Cherqui D, Rahmouni A, Dhumeaux D. Oral contraceptive intake in women with focal nodular hyperplasia of the liver. The Lancet. 1998;352(9141):1679–80.CrossRef
20.
Colli A, Fraquelli M, Massironi S, Colucci A, Paggi S, Conte D. Elective surgery for benign liver tumours. The Cochrane Library. 2007.
21.
Mathieu D, Kobeiter H, Maison P, Rahmouni A, Cherqui D, Zafrani ES, et al. Oral contraceptive use and focal nodular hyperplasia of the liver. Gastroenterology. 2000;118(3):560–4.CrossRefPubMed
22.
Anderson SW, Kruskal JB, Kane RA. Benign hepatic tumors and iatrogenic pseudotumors. Radiographics. 2009;29(1):211–29.CrossRefPubMed
23.
Savastano S, San Bortolo O, Velo E, Rettore C, Altavilla G. Pseudotumoral appearance of peliosis hepatis. AJR Am J Roentgenol. 2005;185(2):558–9.CrossRefPubMed
24.
Torabi M, Hosseinzadeh K, Federle MP. CT of nonneoplastic hepatic vascular and perfusion disorders. Radiographics. 2008;28(7):1967–82.CrossRefPubMed
25.
Iannaccone R, Federle MP, Brancatelli G, Matsui O, Fishman EK, Narra VR, et al. Peliosis hepatis: spectrum of imaging findings. AJR Am J Roentgenol. 2006;187(1):W43–52.CrossRefPubMed
26.
Verswijvel G, Janssens F, Colla P, Mampaey S, Verhelst H, Van Eycken P, et al. Peliosis hepatis presenting as a multifocal hepatic pseudotumor: MR findings in two cases. Eur Radiol. 2003;13 Suppl 4:L40–4.CrossRefPubMed
27.
28.
Kim SH, Lee JM, Kim WH, Han JK, Lee JY, Choi BI. Focal peliosis hepatis as a mimicker of hepatic tumors: radiological-pathological correlation. J Comput Assist Tomogr. 2007;31(1):79–85.CrossRefPubMed
29.
Ferrozzi F, Tognini G, Zuccoli G, Cademartiri F, Pavone P. Peliosis hepatis with pseudotumoral and hemorrhagic evolution: CT and MR findings. Abdom Imaging. 2001;26(2):197–9.CrossRefPubMed
30.
Ferral H, Behrens G, Lopera J. Budd-Chiari syndrome. AJR Am J Roentgenol. 2012;199(4):737–45.CrossRefPubMed
31.
Cura M, Haskal Z, Lopera J. Diagnostic and interventional radiology for Budd-Chiari syndrome. Radiographics. 2009;29(3):669–81.CrossRefPubMed
32.
Brancatelli G, Vilgrain V, Federle MP, Hakime A, Lagalla R, Iannaccone R, et al. Budd-Chiari syndrome: spectrum of imaging findings. AJR Am J Roentgenol. 2007;188(2):W168–76.CrossRefPubMed
33.
Aronson JK. Meyler's side effects of drugs: the international encyclopedia of adverse drug reactions and interactions: Elsevier; 2015.
34.
Erden A. Budd-Chiari syndrome: a review of imaging findings. Eur J Radiol. 2007;61(1):44–56.CrossRefPubMed
35.
Lee HK, Park SJ, Yi BH, Yeon EK, Kim JH, Hong HS. Portal vein thrombosis: CT features. Abdom Imaging. 2008;33(1):72–9.CrossRefPubMed
36.
Mantaka A, Augoustaki A, Kouroumalis EA, Samonakis DN. Portal vein thrombosis in cirrhosis: diagnosis, natural history, and therapeutic challenges. Ann Gastroenterol. 2018;31(3):315–29.PubMedPubMedCentral
37.
Margini C, Berzigotti A. Portal vein thrombosis: The role of imaging in the clinical setting. Dig Liver Dis. 2017;49(2):113–20.CrossRefPubMed
38.
Jha RC, Khera SS, Kalaria AD. Portal Vein Thrombosis: Imaging the Spectrum of Disease With an Emphasis on MRI Features. AJR Am J Roentgenol. 2018;211(1):14–24.CrossRefPubMed
39.
Zhou H, Wang YX, Lou HY, Xu XJ, Zhang MM. Hepatic sinusoidal obstruction syndrome caused by herbal medicine: CT and MRI features. Korean J Radiol. 2014;15(2):218–25.CrossRefPubMedPubMedCentral
40.
Erturk SM, Mortele KJ, Binkert CA, Glickman JN, Oliva MR, Ros PR, et al. CT features of hepatic venoocclusive disease and hepatic graft-versus-host disease in patients after hematopoietic stem cell transplantation. AJR Am J Roentgenol. 2006;186(6):1497–501.CrossRefPubMed
41.
Mortele KJ, Van Vlierberghe H, Wiesner W, Ros PR. Hepatic veno-occlusive disease: MRI findings. Abdom Imaging. 2002;27(5):523–6.CrossRefPubMed
42.
Yang S, Wu J, Lei S. CT Features of Hepatic Veno-occlusive Disease: A Meta-analysis. Acad Radiol. 2018;25(3):328–37.CrossRefPubMed
43.
Dumont C, Lambert M, Van Beers BE. MR imaging findings in a patient with hepatic veno-occlusive disease. Acta Gastroenterol Belg. 2004;67(2):236–8.PubMed
Metadaten
Titel
Hepatic disorders associated with exogenous sex steroids: MR imaging findings
verfasst von
Cathryn L. Hui
Zhen Jiang Lee
Publikationsdatum
06.04.2019
Verlag
Springer US
Erschienen in
Abdominal Radiology / Ausgabe 7/2019
Print ISSN: 2366-004X
Elektronische ISSN: 2366-0058
DOI
https://doi.org/10.1007/s00261-019-01941-4

Weitere Artikel der Ausgabe 7/2019

Interobserver agreement of computed tomography reporting standards for chronic pancreatitis

  • Pancreas

68Ga-PSMA-11 PET/CT in newly diagnosed prostate cancer: diagnostic sensitivity and interobserver agreement

  • Pelvis

Clinicopathological findings and imaging features of intraductal papillary neoplasm of the bile duct: comparison between contrast-enhanced ultrasound and contrast-enhanced computed tomography

  • Hepatobiliary

“Nodule-in-nodule” architecture of hepatocellular carcinoma

  • Classics in Abdominal Radiology

The “hot air balloon” sign

  • Classics in Abdominal Radiology

Recent use of NSAID and NOAC medications are associated with a positive CT arteriogram

  • Interventional Radiology

Neu im Fachgebiet Radiologie

KI-gestütztes Mammografiescreening überzeugt im Praxistest

Mit dem Einsatz künstlicher Intelligenz lässt sich die Detektionsrate im Mammografiescreening offenbar deutlich steigern. Mehr unnötige Zusatzuntersuchungen sind laut der Studie aus Deutschland nicht zu befürchten.

Stumme Schlaganfälle − ein häufiger Nebenbefund im Kopf-CT?

In 4% der in der Notfallambulanz initiierten zerebralen Bildgebung sind „alte“ Schlaganfälle zu erkennen. Gar nicht so selten handelt es sich laut einer aktuellen Studie dabei um unbemerkte Insulte. Bietet sich hier womöglich die Chance auf ein effektives opportunistisches Screening?

Die elektronische Patientenakte kommt: Das sollten Sie jetzt wissen

Am 15. Januar geht die „ePA für alle“ zunächst in den Modellregionen an den Start. Doch schon bald soll sie in allen Praxen zum Einsatz kommen. Was ist jetzt zu tun? Was müssen Sie wissen? Wir geben in einem FAQ Antworten auf 21 Fragen.

Stören weiße Wände und viel Licht die Bildqualitätskontrolle?

Wenn es darum geht, die technische Qualität eines Mammogramms zu beurteilen, könnten graue Wandfarbe und reduzierte Beleuchtung im Bildgebungsraum von Vorteil sein. Darauf deuten zumindest Ergebnisse einer kleinen Studie hin. 

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise